Skip to content

Laura King

A genetically targeted drug aimed at the BRAF mutation shrank tumors in 80 percent of metastatic melanoma patients in a study led by Keith T. Flaherty, reported in the New England Journal of Medicine. Only two FDA-approved drugs currently treat the metastatic disease.

5 min read

5 stories